866405-64-3 | Dorsomorphin (Compound C / HY-13418A)

Chemical type

• Small-molecule inhibitor
• Pyrazolopyrimidine derivative

^[1]

• Small-molecule BMP signaling inhibitor (Type I BMP receptor inhibitor)

^[2]

Key properties

• AMP-activated protein kinase (AMPK) inhibitor

^[1]

• Highly selective inhibitor of BMP type I receptors (ALK2, ALK3, ALK6)
• Does not inhibit BMPR2, allowing MAPK signaling to remain active
• Blocks Smad1/5/8 phosphorylation, suppressing mesoderm and endoderm induction
• Promotes ectodermal/neuroectodermal bias

^[2]

• Pharmacological tool to inhibit AMPK pathway in research
• Used in vitro to reverse protective effects of ANKRD1 knockdown

^[1]

• Direct chemical induction of neuroectodermal cells from human fibroblasts
• Core component of the DSM + TSA cocktail for transdifferentiation

^[2]

Classification by use

• Biochemical pathway inhibitors (AMPK-specific)
• Research chemicals for mechanistic studies

^[1]

• Small molecules for cellular reprogramming
• BMP signaling inhibitors
• Neuroectodermal induction agents

^[2]

A trustworthy factory and manufacturer

1. [Cite:1] ANKRD1 knockdown attenuates doxorubicin-induced dilated cardiomyopathy by regulating mitochondrial dysfunction and oxidative stress through activation of the AMPK/AKT/mTOR pathway, Electronic Journal of Biotechnology, Volume 79, January 2026, 100696
2. [Cite:2] Full small molecule conversion of human fibroblasts to neuroectodermal cells via a cocktail of Dorsomorphin and Trichostatin A, Regenerative Therapy, Volume 15, December 2020, Pages 44-52